1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H2 2020, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.
Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 21, 9, 50, 12 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 2, 18 and 4 molecules, respectively.
Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionMyocardial Infarction - Overview
Myocardial Infarction - Therapeutics Development
Myocardial Infarction - Therapeutics Assessment
Myocardial Infarction - Companies Involved in Therapeutics Development
Myocardial Infarction - Drug Profiles
Myocardial Infarction - Dormant Projects
Myocardial Infarction - Discontinued Products
Myocardial Infarction - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Myocardial Infarction, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Myocardial Infarction - Pipeline by Actinogen Medical Ltd, H2 2020
- Myocardial Infarction - Pipeline by Angion Biomedica Corp, H2 2020
- Myocardial Infarction - Pipeline by Ankasa Regenerative Therapeutics Inc, H2 2020
- Myocardial Infarction - Pipeline by Aposcience AG, H2 2020
- Myocardial Infarction - Pipeline by Applied Therapeutics Inc, H2 2020
- Myocardial Infarction - Pipeline by Aprogen Inc, H2 2020
- Myocardial Infarction - Pipeline by APT Therapeutics Inc, H2 2020
- Myocardial Infarction - Pipeline by AptaTargets SL, H2 2020
- Myocardial Infarction - Pipeline by AstraZeneca Plc, H2 2020
- Myocardial Infarction - Pipeline by Athera Biotechnologies AB, H2 2020
- Myocardial Infarction - Pipeline by Axolo Pharma Inc, H2 2020
- Myocardial Infarction - Pipeline by Bharat Biotech Ltd, H2 2020
- Myocardial Infarction - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
- Myocardial Infarction - Dormant Projects, H2 2020
- Myocardial Infarction - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Myocardial Infarction, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Actinogen Medical Ltd
- Angion Biomedica Corp
- Ankasa Regenerative Therapeutics Inc
- Aposcience AG
- Applied Therapeutics Inc
- Aprogen Inc
- APT Therapeutics Inc
- AptaTargets SL
- AstraZeneca Plc
- Athera Biotechnologies AB
- Axolo Pharma Inc
- Bharat Biotech Ltd
- Boehringer Ingelheim International GmbH
- Cadila Healthcare Ltd
- CardioCreate Inc
- Cardior Pharmaceuticals GmbH
- CeleCor Therapeutics Inc
- Celixir Ltd
- CellProthera SAS
- CFM Pharma Holding BV
- Curacle Co Ltd
- Cynata Therapeutics Ltd
- DeckTherapeutics Inc
- Diffusion Pharmaceuticals Inc
- Domainex Ltd
- Eight Plus One Pharmaceutical Co Ltd
- EndoProtech Inc
- Ever Supreme Bio Technology Co Ltd
- Evotec SE
- EyeGene Inc
- Faraday Pharmaceuticals Inc
- General Regeneratives Shanghai Ltd
- Generium
- GNT Pharma Co Ltd
- Hemostemix Inc
- Honya Medical Inc
- HUYA Bioscience International LLC
- Idorsia Pharmaceutical Ltd
- iHeart Japan Corp
- InCarda Therapeutics Inc
- Innolife Co Ltd
- Inotrem SA
- IPS Heart Inc
- Kine Sciences
- Lee's Pharmaceutical Holdings Ltd
- LTT Bio-Pharma Co Ltd
- MandalMed Inc
- Marizyme Inc
- Merck & Co Inc
- Mesoblast Ltd
- MIFCOR Inc
- MimeTech Srl
- Mirae Cell Bio Co Ltd
- Miragen Therapeutics Inc
- New World Laboratories Inc
- Novartis AG
- NuvOx Pharma LLC
- OMEICOS Therapeutics GmbH
- OP2 Drugs SAS
- Opsona Therapeutics Ltd
- OtiTopic LLC
- Oxstem Ltd
- Pharmahungary Group
- Primary Peptides Inc
- Quark Pharmaceuticals Inc
- Qurgen Inc
- R Pharm
- Reata Pharmaceuticals Inc
- Recardio GmbH
- RegeneRx Biopharmaceuticals Inc
- ResoTher Pharma ApS
- Rubicon Biotechnology Inc
- Sentan Pharma Inc
- Serca Pharmaceuticals AS
- Serpin Pharma LLC
- Silver Creek Pharmaceuticals Inc
- Sorrento Therapeutics Inc
- T&R Biofab Co Ltd
- TaiGen Biotechnology Co Ltd
- Takeda Pharmaceutical Co Ltd
- Thrombolytic Science International LLC
- Translational Sciences Inc
- Vaxil Bio Therapeutics Ltd
- XBiotech Inc
- Xcelthera INC
- Yichang Humanwell Pharmaceutical Co Ltd
- Yuyu Pharma Inc
- Zensun (Shanghai) Sci & Tech Co Ltd
